CORONA Remedies Limited (CORONA)
Analyst/Investor presentation
AI summary
- Q1FY27 revenue 422.4 Cr +21.9% y-y; EBITDA 93.1 Cr +33.5% (margin 22.0%, +190 bps); PAT 60.1 Cr +30.1% (margin 14.2%, +90 bps)
- Renewed EU-GMP certification and inaugurated advanced hormone facility in June 2026
- Fastest growing company among top 30 pharma in IPM with 1.9x growth vs IPM
- Chronic therapies contribute 73.4% of Q1FY27 revenue; focus on women’s health and chronic segments
- Strategic growth via MR productivity, new therapeutic areas, acquisitions, and overseas expansion
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 CORONA — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add CORONA to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on CORONA Remedies Limited
Important.
The summary above is generated automatically from CORONA Remedies Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.